222 related articles for article (PubMed ID: 24845630)
1. Probody therapeutics for targeting antibodies to diseased tissue.
Polu KR; Lowman HB
Expert Opin Biol Ther; 2014 Aug; 14(8):1049-53. PubMed ID: 24845630
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of protease activity by Probody therapeutic activation.
Wong KR; Menendez E; Craik CS; Kavanaugh WM; Vasiljeva O
Biochimie; 2016 Mar; 122():62-7. PubMed ID: 26546838
[TBL] [Abstract][Full Text] [Related]
4. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
Autio KA; Boni V; Humphrey RW; Naing A
Clin Cancer Res; 2020 Mar; 26(5):984-989. PubMed ID: 31601568
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
6. Homogeneously modified immunoglobulin domains for therapeutic application.
Liu T; Du J; Luo X; Schultz PG; Wang F
Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
[TBL] [Abstract][Full Text] [Related]
7. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
8. Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates.
Oberoi HK; Garralda E
Clin Cancer Res; 2021 Aug; 27(16):4459-4461. PubMed ID: 34135020
[TBL] [Abstract][Full Text] [Related]
9. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
Niwa R; Satoh M
J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
[TBL] [Abstract][Full Text] [Related]
10. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
12. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Carter PJ; Lazar GA
Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
Chang L; Li CH; Gao J
Yao Xue Xue Bao; 2015 May; 50(5):516-20. PubMed ID: 26234129
[TBL] [Abstract][Full Text] [Related]
14. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
15. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
Igawa T
Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
17. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
18. Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes.
Vasiljeva O; Menendez E; Nguyen M; Craik CS; Michael Kavanaugh W
Sci Rep; 2020 Apr; 10(1):5894. PubMed ID: 32246002
[TBL] [Abstract][Full Text] [Related]
19. Bispecific human IgG by design.
Carter P
J Immunol Methods; 2001 Feb; 248(1-2):7-15. PubMed ID: 11223065
[TBL] [Abstract][Full Text] [Related]
20. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
